

OCEANARIUM (MAURITIUS) LTD

UNAUDITED CONDENSED FINANCIAL STATEMENTS FOR THE QUARTER ENDED DECEMBER 31, 2022

The Directors are pleased to present the unaudited condensed Financial Statements of the Company for the quarter ended December 31, 2022.

1. CONDENSED STATEMENT OF FINANCIAL POSITION

ASSETS

Non-current assets Current assets

EQUITY AND LIABILITIES

Equity and reservesEquity holders' interests **Total equity and reserves**

Non-current liabilities

Current liabilities

Total equity and liabilities

THE COMPANY			
Unaudited	Audited		
as at	as at		
Dec 31,	Jun 30,		
2022	2022		
Rs'000	Rs'000		
659,507	651,554		
44,847	65,500		
704,354	717,054		
514,299	522,372		
514,299	522,372		
-			
142,418	142,419		
47,637	52,263		
704,354	717,054		

2. CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Turnover Operating loss

Net finance costs

Loss before taxation
Income tax credit

Loss for the period

Total comprehensive income for the period

Number of ordinary shares ('000)

- In issue

Loss per share (Rs.)

Net Asset Value per share (Rs.)

THE COMPANY

Unaudited -	quarter to	Unaudited - 6	months to
Dec 31, 2022 Rs'000	Dec 31, 2021 Rs'000	Dec 31, 2022 Rs'000	Dec 31, 2021 Rs'000
23,512	25,873	56,881	38,692
(7,342)	(7,466)	(4,617)	(17,461)
(2,504)	(2,184)	(5,109)	(4,306)
(9,845)	(9,650)	(9,726)	(21,767)
1,674	1,419	1,653	3,200
(8,172)	(8,231)	(8,073)	(18,567)
(8,172)	(8,231)	(8,073)	(18,567)
F7 200	50.000		F0 000
57,300	50,300	57,300	50,300
(0.14)	(0.16)	(0.00)	(0.00)
-	-	8.98	9.03

3. CONDENSED STATEMENT

Net cash from operating activities
Net cash used in investing activities
Net cash from/(used in) financing activities

Increase/(Decrease) in cash and cash equivalents

Opening cash and cash equivalents at July 1, Increase/(Decrease) Effect of exchange rate changes

At December 31,

THE COMPANY

	Unaudited - 6 months to		
	Dec 31, 2022 Rs'000	Dec 31, 2021 Rs'000	
	9,426 (20,362) 14,118	13,240 (48,933) (36,890)	
	3,182	(72,583)	
	3,958 3,182	91,963 (72,583)	
-	7,140	19,380	

4. CONDENSED STATEMENT OF

At July 1, 2022

Loss for the period Issue of shares

Other comprehensive income for the period

At December 31, 2022

At July 1, 2021

Loss for the period

At December 31, 2021

Issue of shares

Other comprehensive income for the period

THE COMPANY

Share Capital	Revaluation and other Reserves	Retained Earnings	Total		
Rs'000	Rs'000	Rs'000	Rs'000		
528,000	550	(6,178)	522,372		
-	-	(8,073)	(8,073)		
-	-	-	-		
	-	-	-		
528,000	550	(14,251)	514,299		
458,000	-	18,094	476,094		
-	-	(18,567)	(18,567)		
-	-	-	-		
-	-	-	-		
458,000	-	(473)	457,527		

NOTES

The unaudited interim quarterly condensed Financial Statements are in compliance with International Financial Reporting Standards (IFRS) and have been prepared on the same basis as the accounting policies set out in the statutory financial statements of the Company for the year ended June 30, 2022, except for the adoption of published Standards and any amendments and Interpretations issued now effective. This communiqué is issued pursuant to DEM Rule 17 and the Securities Act 2005.

RESULTS & PROSPECTS

After a promising first quarter, the second quarter was a slow start. The results of the first two months of the second quarter were below expectations. The marketing initiatives we have initiated, started to show results in December, especially with regards to a substantial increase in non-resident visitors.

We are confident that 2023 will be better with the initiatives we are putting in place.

By order of the Board

Eclosia Secretarial Services Ltd Secretary

Date: February 7, 2023

Copies of the condensed financial statements and the statement of direct and indirect interests of officers of the Company (required under rule 8(2) (m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007), are available free of charge, upon request made to the Company Secretary, Eclosia Group Headquarters, Gentilly, Moka, Mauritius.

The Board of Directors of Oceanarium (Mauritius) Ltd accepts full responsibility for the accuracy of the information contained in this report.

BRN: C16141503